Implantable glucose sensor with prolonged accuracy

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$806,213.00
Award Year:
2008
Program:
SBIR
Phase:
Phase II
Contract:
2R44DK074243-02A2
Agency Tracking Number:
DK074243
Solicitation Year:
2008
Solicitation Topic Code:
n/a
Solicitation Number:
PHS2007-2
Small Business Information
MC3, INC.
MC3, INC., 3550 W LIBERTY RD, STE 3, ANN ARBOR, MI, 48103
Hubzone Owned:
Y
Socially and Economically Disadvantaged:
Y
Woman Owned:
Y
Duns:
806687406
Principal Investigator:
MELISSA REYNOLDS
(734) 995-9089
REYNOLDS@MC3CORP.COM
Business Contact:
(734) 995-9089
koster@mc3corp.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): The goal of this study is to fabricate an intravascular glucose sensor that functions accurately for 7 days in vivo. We will utilize a glucose membrane design devised in Phase I to develop a custom outer membrane that has covalently attached bioactive sites to resist biofouling, allows for suitable glucose diffusion, and prevents leaching of potentially toxic by-products. This membrane will be applied to needle-type, amperometric glucose sensor. The versatility of the s ensor design will allow easy incorporation into a patient's bloodstream through a central access catheter. The catheter will be designed for 7 day use in the intensive care unit, and will be complete with a hemostatic connector for attaching to an access l ine, and the electrical connections to an amplifier/display unit. The final prototype will be evaluated for cytotoxicity, hemocompatibilty, and accuracy both using in vitro and in vivo methods. Continuous monitoring of blood glucose levels has been an elus ive goal, but would greatly improve the care for critically ill patients in managing insulin therapy. PUBLIC HEALTH RELEVANCE: The goal in this grant is to make an intravascular glucose sensor that measures blood glucose levels continuously for 7 days. By maintaining sensor function, this technology will provide health care professionals with immediate changes in patient health and decrease complications. Currently sudden changes in glucose levels are not detected leading to increased health care costs and increased risks to patients.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government